1nessAgency Insights

The FDA granted accelerated approval to Rybrevant Faspro for recurrent or metastatic head and neck squamous cell carcinoma, marking the first new drug approval in this indication in a decade . For healthcare marketers at cancer centers and academic medical centers, this represents a rare moment: the

The U.S. Food and Drug Administration approved Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) in 2026, marking the first plasmid DNA-based immunotherapy cleared in the country. The therapy treats adults with recurrent respiratory papillomatosis (RRP), a rare HPV-driven diseas

Popular artificial intelligence models are calculating medication doses incorrectly, with some errors reaching dangerous levels, according to research released by Doximity in 2026 . The findings arrive as healthcare systems race to deploy AI-powered patient engagement tools, symptom checkers, and me

Zocdoc just opened its provider database to AI agents that can book appointments, verify insurance, and schedule visits without human intervention, a move that signals patient access is becoming automated infrastructure . The decision transforms a consumer-facing app into a platform other AI systems

Humana and Athenahealth announced an expansion of their electronic prior authorization partnership in 2026, a development that signals a shift in where healthcare marketing battles will be won and lost. For health systems and specialty practices, the integration of automated prior authorization syst

Tenet Healthcare weathered surgical volume headwinds and rising uninsured patient counts in Q3 2026 by doubling down on high-acuity cases, a strategic bet that redefines where hospital marketers should concentrate patient acquisition dollars. The move signals that the old playbook of chasing every ad

Publicis Groupe closed its $2.2 billion all-cash acquisition of data collaboration platform LiveRamp in 2026, marking the holding company's largest deal since its $4.4 billion Epsilon purchase in 2019 . For healthcare marketers navigating HIPAA compliance while trying to reach patients across fragme

Medicare beneficiaries with stand-alone prescription drug plans will face average monthly premiums jumping from $34 to $51 in 2027, a 50% increase that puts real money at stake while political claims of drug pricing victories ring hollow . This isn't a minor adjustment. For the nearly 25 million Amer

The Federal Trade Commission approved Publicis Groupe's $2.2 billion acquisition of LiveRamp on October 20, 2026, but the five-year "neutrality" conditions attached to the deal signal a new era of regulatory scrutiny for healthcare marketers who rely on third-party data infrastructure . The order ma

A new bill targeting the No Surprises Act's arbitration process moves through Congress in 2026, threatening to reshape how hospitals, insurers, and out-of-network providers resolve billing disputes, and by extension, how healthcare organizations message their pricing transparency commitments to pat

Healthcare organizations faced a stark choice in 2026: pay more or lose staff. At least 50 hospitals and health systems announced wage increases this year, a compensation wave that reshapes not just HR departments but marketing budgets, patient acquisition strategies, and the fundamental economics o

Google confirmed this month it is testing branded prescription drug ads in AI Mode and AI Overviews, the first time one of advertising's most tightly regulated categories has entered the company's generative AI search platform . The move arrives as the FDA simultaneously expands its regulatory infras

A new fault line opened in healthcare in 2026: insurers claim artificial intelligence could add billions in costs through automated billing that identifies previously missed charges, while revenue cycle companies argue AI will reduce waste and improve accuracy. The disagreement exposes how technolog

Hospitals deployed AI to maximize reimbursements. Insurers countered with AI to minimize payouts. The predictable result in 2026: medical costs are climbing as these algorithms battle each other in a high-stakes game of computational chess, and healthcare marketers now face a credibility crisis that

The FDA approved Fayuvi on September 17, 2026, making it the first treatment for Sanfilippo syndrome type A, a rare pediatric disease that until now had no therapy to alter its course . For healthcare marketing leaders, this approval signals a fundamental shift in how to position gene therapies for u

Payers are deploying AI to deny claims faster than hospitals can appeal them. While healthcare providers debate AI ethics and pilot programs, commercial insurers have already embedded machine learning into claims adjudication workflows, shifting the balance of power in revenue cycle negotiations. Fo

A lawsuit that started in 2019 is about to reshape how health plans define "employee", and the implications for healthcare marketers are stark. Court papers filed in September 2026 indicate a settlement may be imminent in Data Marketing Partnership v. Department of Labor, a case that could legitimi

The most consequential shift in healthcare provider operations in 2026 is not happening in the clinic , it is happening in the back office. Artificial intelligence is automating prior authorizations, denials management, and claims processing at a scale that is compressing revenue cycle timelines fro

Eight states carved out portions of the $50 billion federal Rural Health Transformation Program to launch venture-style catalyst funds, injecting $20 million annually into health tech startups targeting rural communities . The money represents a sharp turn from traditional grant-making: states now o

Networks this size don't market themselves. Individual hospitals within them often carry legacy brand identities, fragmented digital presences, and patient engagement tools built for standalone facilities , not for coordinated regional systems competing against urban health systems for the same pati

The federal government is writing a check that could redefine how health systems market cardiovascular services. ARPA-H, the Advanced Research Projects Agency for Health, is investing $62 million to develop agentic AI agents for heart care, marking the first major federal investment in autonomous AI

Boston Scientific restored remote monitoring capabilities for its cardiac implantable electronic devices (CIEDs) following a service disruption that left patients and clinicians without real-time data transmission from pacemakers, defibrillators, and cardiac resynchronization therapy devices [1]. Th

The FDA is simultaneously reshuffling its senior leadership and opening public comment on how to regulate generative AI-enabled medical devices , and the window for healthcare marketers to shape, anticipate, and position around that regulatory reality is closing faster than most organizations recogn

The approval targets adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent regimens [1]. Between 90% and 95% of all pancreatic cancer diagnoses fall into the adenocarcinoma category, meaning this is not a niche pat

Stanford Health Care announced plans in 2026 to eliminate 95 positions, with the majority concentrated in information technology [1]. For a system that generated over $6 billion in annual revenue in recent fiscal years and sits at the center of Silicon Valley's health innovation ecosystem, the move